FDA's safety assessment of medicines does not diminish after drugs are approved for marketing. Although the premarket phase of study is very intensive, much work still remains to monitor approved drugs over time. No drug is risk-free, and it is not uncommon for new information to be discovered after a drug is on the market and being used by larger numbers of patients. Such information helps provide a better picture of drug risks, enables FDA to give health care professionals and patients the latest information on potential or newly identified risks, and strengthens FDA's ability to safeguard patients against unacceptable risks.
In recent years, FDA's Center for Drug Evaluation and Research (CDER) has taken many steps to enhance the quality, accountability, and timeliness of its postmarket drug safety decisions. As a result, the Agency now oversees the safety of marketed drugs with the same emphasis it has for premarket drug review. These efforts include the development of important new scientific tools to enhance detection of potential drug safety issues that occur once a drug is on the market and new methods for planning, managing, tracking, and communicating about those issues.
Visit this link for a complete 21-page April 2012 report of FDA's Center for Drug Evaluation's work to enhance the Agency's postmarket drug safety. Visit this link for a six-page highlights version of the same report.
- Vaccines for Use During Pregnancy to Protect Young Infants from Disease – FDA Update
- FDA Basics Webinar: Practice the art of sun protection
- FDA Basics Webinar: "Mini-Sentinel," FDA's New Tool for Monitoring the Safety of FDA-Approved Medical Products
- FDA Basics Webinar - April 27, 2015: Drug Trials Snapshots
- FDA Webinar on Prescription Drug Shortages
- When previously recalled products are back on the shelves, how can I be sure that it is okay to buy them?
- What do consumers need to know about the recall of shell eggs?
- What is FDA Basics for Industry?
- FDA Basics Webinar- August 31, 2015: Food Safety: Bad Weather Basics
- July: CBER's Direct Recall Classification Program
- FDA Basics Webinar, June 17, 2013: Biological Products: Part 1
- Is it true that "OTC (Over the Counter)" products can prevent SIDS?
- FDA's Pesticide Program
- Recall Process for FDA-Regulated Products
- Where can I find information about adverse reactions to a medicine prescribed for my child?
- Where can I find information about medicines prescribed for my child?
- FDA Webinar on Protecting Your Child's Health Through Safe and Effective Vaccines
- FDA Webinar on Safety of the Blood Supply
- How did the Federal Food, Drug, and Cosmetic Act come about?
- Materials from Webinar on Access to Investigational Drugs
- How do I find the latest information on the Web site? How do I sign up for e-mails and alerts?
- What is a docket? How do I submit comments to a docket? How do I find comments submitted to a docket?
- Can I buy medical products online? How do I know they're safe?
- FDA Basics Webinar: FDA CBER Mini-Sentinel Program
- FDA Basics Webinar - November 24, 2014: Drug Shortages